Management of intermittent claudication with pentoxifylline: meta-analysis of randomized controlled trials.

OBJECTIVE: To evaluate the efficacy of pentoxifylline therapy in improving the walking capacity of patients with moderate intermittent claudication. DATA SOURCES: A search of MEDLINE for trials published between 1976 and 1994 inclusive, and a bibliographic review of all articles retrieved. STUDY SELECTION: Randomized, placebo-controlled, double-blind clinical trials were selected that evaluated the pain-free walking distance (the distanced walked on a treadmill before the onset of calf pain) and the absolute claudication distance (the maximum distance walked on a treadmill) among patients with moderate intermittent claudication. Twelve study groups in 11 trials were included in the analysis. DATA EXTRACTION: In addition to information regarding the trial design, patient characteristics, dosages and treatment periods, the means and standard deviations were collected for both the pain-free walking and absolute claudication distances. Trial quality was also assessed. DATA SYNTHESIS: Overall, there was a statistically significant improvement in the pain-free walking distance after pentoxifylline therapy (weighted mean difference 29.4 m [95% confidence interval (CI) 13.0 to 45.9 m]); this finding was based on a total sample of 612 patients (308 in the treatment groups and 304 in the control groups). A significant improvement was also noted in the absolute claudication distance (weighted mean difference 48.4 m [95% CI 18.3 to 78.6 m]); this was based on a total sample of 511 patients (258 in the treatment group and 253 in the control group). In a sensitivity analysis of the pain-free walking distance, significant treatment effects and no statistically significant heterogeneity were found when only trials were included that were "medically eligible" (involved patients with stage II disease and a pain-free walking distance of 50 to 200 m). In a similar sensitivity analysis of the absolute claudication distance, the two conditions resulting in a significant treatment effect and no significant heterogeneity were the inclusion of "medically eligible" trials and those with a shorter treatment duration (13 weeks or less). CONCLUSION: Pentoxifylline therapy may be efficacious in improving the walking capacity of patients with moderate intermittent claudication. However, properly conducted clinical trials are required to provide a true estimate of the benefit.     

Leg symptoms in peripheral arterial disease: associated clinical characteristics and functional impairment

CONTEXT: Persons with lower-extremity peripheral arterial disease (PAD) are often asymptomatic or have leg symptoms other than intermittent claudication (IC). OBJECTIVE: To identify clinical characteristics and functional limitations associated with a broad range of leg symptoms identified among patients with PAD. DESIGN, SETTING, AND PARTICIPANTS: Cross-sectional study of 460 men and women with PAD and 130 without PAD, who were identified consecutively, conducted between October 1998 and January 2000 at 3 Chicago-area medical centers. MAIN OUTCOME MEASURES: Ankle-brachial index score of less than 0.90; scores from 6-minute walk, accelerometer-measured physical activity over 7 days, repeated chair raises, standing balance (full tandem stand), 4-m walking velocity, San Diego claudication questionnaire, Geriatric Depression Score Short-Form, and the Walking Impairment Questionnaire. RESULTS: All groups with PAD had poorer functioning than participants without PAD. The following values are for patients without IC vs those with IC. Participants in the group with leg pain on exertion and rest (n = 88) had a higher (poorer) score for neuropathy (5.6 vs 3.5; P<.001), prevalence of diabetes mellitus (48.9% vs 26.7%; P<.001), and spinal stenosis (20.8% vs 7.2%; P =.002). The atypical exertional leg pain/carry on group (exertional leg pain other than IC associated with walking through leg pain [n = 41]) and the atypical exertional leg pain/stop group (exertional leg pain other than IC that causes one to stop walking [n = 90]) had better functioning than the IC group. The group without exertional leg pain/inactive (no exertional leg pain in individual who walks 相似文献   

周围动脉硬化性疾病与脑卒中及冠心病的相关性

目的 探讨我国周围动脉性疾病(PAD)与冠心病和脑卒中的相关性.同时调查在下肢缺血的周围动脉性疾病患者中凉、麻、疼痛及间歇跛行等症状的发生率及其与踝臂指数(ABI)下降程度的关系.方法 前瞻性地对2006年3月至2007年12月心脏科、神经科和血管科患者进行统一ABI测量并记录病史、射血分数、冠状动脉造影和颈动脉超声结果 ,统计ABI与观察指标的相关性.对PAD患者记录其凉、麻、痛、间歇跛性行和溃疡等症状的程度,并统计各种症状的发生率及其与ABI的相关性.结果 心脏科132例患者中,ABI<0.9的发生率为29.5%,神经科124例患者中,ABI<0.9的总发生率为17.7%.随着ABI的降低,射血分数逐渐降低,冠状动脉和颈动脉病变程度也逐渐加重.在血管科患者中,ABI均值越低,凉、麻、痛、间歇跛行的程度越重,各种症状为重度时ABI的值大致都在0.4左右.结论 29.5%的的冠心病和17.7%的脑卒中患者合并PAD,患者中7.2%的人同时患有这3种疾病.PAD的严重程度与冠心病和脑卒中的严重程度相关.在PAD患者中,随着ABI的降低,肢体缺血症状逐渐加重,当ABI<0.40时各种症状显著加剧.     

西洛他唑联合前列腺素E1治疗2型糖尿病合并下肢动脉病变早期疗效观察

目的 探讨西洛他唑联合前列腺素E1治疗2型糖尿病合并下肢动脉病变(PAD)的早期疗效.方法 2型糖尿病合并PAD早期患者60例,按就诊时间先后次序随机分为研究组和对照组各30例.在常规给予饮食干预、运动治疗以及降糖药物治疗基础上,对照组前列腺素E1注射液10 μg加入生理盐水100 ml中静脉滴注,研究组在对照组基础上口服西洛他唑片1 00 mg,bid.两组疗程均为1个月.检测并比较治疗前、后两组的踝肱指数(ABI)、脉搏波传导速度(PWV)、临床症状评分,比较两组治疗有效率.结果 两组治疗后ABI、PWV评分均较治疗前明显升高,差异有统计学意义(P＜0.05～0.01),临床症状评分较治疗前明显降低,差异有统计学意义(P＜0.01);治疗后研究组PWV评分及治疗有效率较对照组明显升高,临床症状评分较对照组明显降低,差异均有统计学意义(P均＜0.05).结论 西洛他唑联合前列腺素E1治疗2型糖尿病合并PAD患者,具有协同作用,可明显改善下肢动脉病变,不增加出血倾向,疗效可靠,值得临床推广应用.     

Peripheral arterial disease detection, awareness, and treatment in primary care

CONTEXT: Peripheral arterial disease (PAD) is a manifestation of systemic atherosclerosis that is common and is associated with an increased risk of death and ischemic events, yet may be underdiagnosed in primary care practice. OBJECTIVE: To assess the feasibility of detecting PAD in primary care clinics, patient and physician awareness of PAD, and intensity of risk factor treatment and use of antiplatelet therapies in primary care clinics. DESIGN AND SETTING: The PAD Awareness, Risk, and Treatment: New Resources for Survival (PARTNERS) program, a multicenter, cross-sectional study conducted at 27 sites in 25 cities and 350 primary care practices throughout the United States in June-October 1999. PATIENTS: A total of 6979 patients aged 70 years or older or aged 50 through 69 years with history of cigarette smoking or diabetes were evaluated by history and by measurement of the ankle-brachial index (ABI). PAD was considered present if the ABI was 0.90 or less, if it was documented in the medical record, or if there was a history of limb revascularization. Cardiovascular disease (CVD) was defined as a history of atherosclerotic coronary, cerebral, or abdominal aortic aneurysmal disease. MAIN OUTCOME MEASURES: Frequency of detection of PAD; physician and patient awareness of PAD diagnosis; treatment intensity in PAD patients compared with treatment of other forms of CVD and with patients without clinical evidence of atherosclerosis. RESULTS: PAD was detected in 1865 patients (29%); 825 of these (44%) had PAD only, without evidence of CVD. Overall, 13% had PAD only, 16% had PAD and CVD, 24% had CVD only, and 47% had neither PAD nor CVD (the reference group). There were 457 patients (55%) with newly diagnosed PAD only and 366 (35%) with PAD and CVD who were newly diagnosed during the survey. Eighty-three percent of patients with prior PAD were aware of their diagnosis, but only 49% of physicians were aware of this diagnosis. Among patients with PAD, classic claudication was distinctly uncommon (11%). Patients with PAD had similar atherosclerosis risk factor profiles compared with those who had CVD. Smoking behavior was more frequently treated in patients with new (53%) and prior PAD (51%) only than in those with CVD only (35%; P <.001). Hypertension was treated less frequently in new (84%) and prior PAD (88%) only vs CVD only (95%; P <.001) and hyperlipidemia was treated less frequently in new (44%) and prior PAD (56%) only vs CVD only (73%, P<.001). Antiplatelet medications were prescribed less often in patients with new (33%) and prior PAD (54%) only vs CVD only (71%, P<.001). Treatment intensity for diabetes and use of hormone replacement therapy in women were similar across all groups. CONCLUSIONS: Prevalence of PAD in primary care practices is high, yet physician awareness of the PAD diagnosis is relatively low. A simple ABI measurement identified a large number of patients with previously unrecognized PAD. Atherosclerosis risk factors were very prevalent in PAD patients, but these patients received less intensive treatment for lipid disorders and hypertension and were prescribed antiplatelet therapy less frequently than were patients with CVD. These results demonstrate that underdiagnosis of PAD in primary care practice may be a barrier to effective secondary prevention of the high ischemic cardiovascular risk associated with PAD.     

踝臂指数评价糖尿病合并下肢动脉病患者治疗效果研究

目的探讨踝臂指数(ABI)作为糖尿病合并下肢动脉病(PAD)患者治疗效果评价指标的价值。方法糖尿病合并PAD患者106例,随机分为两组:单纯药物治疗(A组)64例,其中男38例,女26例;平均(74±6)岁;介入治疗+药物治疗(B组)42例,其中男29例,女13例,平均(73±5)岁。分别于治疗前及治疗后1、3、6、12个月检测ABI。结果老年糖尿病合并PAD患者治疗前ABI<0.90。B组治疗后1、3、6、12个月的ABI与治疗前相比,差异均有统计学意义(P<0.05)。B组中11例于治疗后12个月ABI<0.90,经下肢动脉造影证实支架内再狭窄。治疗后1、3、6、12个月两组的ABI比较,差异均有统计学意义(P<0.01)。结论介入治疗能够及早改善老年糖尿病合并PAD患者的血运,比单纯药物治疗疗效显著。ABI在评价治疗效果中起着重要的作用。     

运动训练对老年下肢动脉硬化闭塞症非介入术患者的疗效观察

目的 通过6MWT、CPET、ABI等评估方法,对老年下肢动脉硬化闭塞症行非介入治疗术患者进行有氧运动等治疗干预,观察其疗效。 方法 入选下肢动脉硬化闭塞症非介入治疗术患者65例,随机分为对照组和研究组,2组观察前后均行6MWT、CPET评估和ABI值检测,测得6MWD,跛行距离、VO_2peak、无氧阈、METs、ABI等值。对照组行常规治疗无规范运动训练干预,研究组在常规治疗基础上,根据CPET结果制定个体化运动处方,指导运动训练3个月,3个月后复查6MWT、CPET和ABI等值。 结果 研究组运动训练3个月后,6MWT结果显示,步行距离较干预前增加75.75 m,跛行距离增加71.4 m。CPET结果显示,与干预前比较VO_2peak增加169.2 ml/min,峰值kgVO₂增加,2.46 ml/(kg·min),AT值增加2.19 ml/(kg·min),代谢当量增加0.5 METs,ABI值增加0.08,上述各项值与干预前比较差异均有统计学意义(P＜0.05)。研究组运动训练3个月后与对照组同期比较,各项指标差异均有统计学意义(P＜0.05)。 结论 个体化运动处方指导下的有氧运动训练能有效改善老年下肢动脉硬化闭塞症非介入术患者症状和步行距离、提高运动耐力和ABI值。      

踝臂指数评价血液透析患者下肢外周动脉病多中心临床研究

目的通过测量踝臂指数(Ankle-brachial index, ABI)评价我国慢性肾功能不全(chronic renal failure, CRF)血液透析(hemodialysis, HD)患者下肢外周动脉病(peripheral arterial disease, PAD)的患病情况.方法对连续入选的271例行HD的CRF患者进行踝臂指数测定,并进行资料收集和统计学处理.结果 271例患者中61例合并下肢外周动脉病(平均ABI 0.62),其中只有4例(6.6%)患者得到了明确的诊断.PAD组与非PAD组患者相比,年龄(P=0.000)、糖尿病史(P=0.000)、血脂异常史(P=0.000)、吸烟量(P=0.002)和血肌酐水平(P=0.000)有统计学意义,而吸烟史(P=0.087)、高血压病史(P=0.053)无统计学意义.结论血液透析患者容易合并下肢PAD,ABI筛查下肢PAD简便易行;血液透析患者合并下肢PAD多见于高龄、糖尿病、血脂异常患者和大量吸烟患者.     

前列腺素E1脂微球载体制剂联合西洛他唑治疗老年下肢动脉硬化闭塞症的疗效分析

目的 探讨前列腺素E1脂微球载体制剂(Lipo-PGE1)联合西洛他唑对老年下肢动脉硬化闭塞症(ASO)的疗效。 方法 以入院病例号为编号,根据随机数字表,将160例老年ASO患者随机分成3组,Lipo-PGE1组(53例)、西洛他唑组(52例)、联合组(55例)。治疗2个疗程后比较临床疗效、血流动力学变化、甲襞微循环、踝肱指数改善及炎症因子改变情况。 结果 联合组疗效、总有效率均优于西洛他唑组和Lipo-PGE1组(P<0.05),西洛他唑组和Lipo-PGE1组有效率对比,差异无统计学意义(P>0.05);联合组的足背动脉处的峰值血流速度、血流搏动指数、阻力指数均低于西洛他唑组和Lipo-PGE1组(P<0.05),Lipo-PGE1组峰值血流速度、血流搏动指数、阻力指数均低于西洛他唑组(P<0.05);联合组的甲襞微循环积分和ABI均优于其他2组(P<0.05),Lipo-PGE1组甲襞微循环积分和ABI优于西洛他唑组(P<0.05);联合组的C反应蛋白(CRP)、肿瘤坏死因子α(TNF-α)、白介素-6(IL-6)和细胞间黏附分子-1(ICAM-1)均低于其他2组(P<0.05),Lipo-PGE1组CRP、TNF-α、IL-6和ICAM-1低于西洛他唑组(P<0.05)。 结论 Lipo-PGE1联合西洛他唑可彼此增加治疗老年ASO的临床疗效,有效改善患者血流动力学水平,临床治疗效果值得肯定。      

银杏叶提取物联合前列腺素E1治疗糖尿病下肢血管病变的研究

目的 探讨银杏叶提取物（EGB）注射液联合前列腺素E1（PGE1）注射液治疗糖尿病下肢血管病变（PAD）的有效性和安全性.方法 将100例糖尿病PAD患者随机分为两组,对照组50例给予PGE1注射液静脉注射治疗;治疗组在此治疗基础上给予EGB注射液静脉注射治疗.2周后比较两组治疗前后临床症状体征、血液流变学相关指标和踝肱指数（ABI）指标的变化.结果 治疗组总有效率为94.0％,对照组总有效率为80.0％,两组治疗结果比较有统计学意义（P＜0.05）;2组血液流变学明显改善,ABI水平显著提高,治疗前后指标比较P＜0.05,治疗组指标改善明显优于对照组,差异均有统计学意义（P＜0.05）.结论 银杏叶提取物注射液联合前列腺素E1注射液能缓解糖尿病下肢血管病变患者临床症状,改善血液流变学和踝肱指数,有显著的临床疗效.     

超声消融联合球囊扩张和支架置入对下肢动脉长段闭塞的临床研究

目的：通过与单独球囊扩张和支架植入比较,评价超声消融联合球囊扩张和支架植入治疗下肢动脉长段闭塞的疗效及安全性。方法筛选我院2010年1月～2013年9月下肢动脉闭塞症患者,选取满足条件的40例存在长段动脉闭塞患者。随机分为2组,治疗组采用超声消融联合球囊扩张和支架植入治疗,对照组采用单纯球囊扩张和支架植入治疗。观察治疗组与对照组两组术前、术后2周患者跛行距离、足部皮温及ABI变化。结果 A组与B组中共11例患者下肢溃烂,术后经局部换药后2周内全部愈合。 A组成功率为97．0％,而B组成功率为87．1％．A组和B组术后2周与术前相比,足部皮温、ABI及间歇性跛行距离均得到明显改善,具有统计学意义（P＜0．05）。术后2周A组与B组比较,足部皮温、ABI及间歇性跛行距离改善无统计学意义（P＞0．05）。术后造影A组较B组有更丰富的侧枝循环。手术并发症：A组并发症发生率6．1％,B组并发症发生率19．3％．结论血管内超声消融联合球囊扩张成形和支架植入治疗下肢动脉完全闭塞比单纯球囊扩张和支架植入的成功率高、并发症少。血管内超声消融联合球囊扩张成形和支架植入治疗下肢动脉完全闭塞的长期疗效有待进一步观察。     

吸烟对下肢动脉疾病影响的研究

目的分析吸烟对下肢外周动脉疾病(PAD)的影响。方法测定北京及上海地区28所医院住院的3379例男性患者(年龄40～98岁)的踝臂指数,踝臂指数≤0.9诊断为PAD。分为吸烟组2253例,非吸烟组1126例。并采用问卷调查表进行资料收集和统计学处理。结果吸烟组踝臂指数(1.00±0.24)显著低于非吸烟组(1.03±0.22,P<0.05)。吸烟组2253例,PAD患病人数562例,患病率为24.94%,非吸烟组1126例,PAD患病人数232例,患病率为20.60%,年龄调整后相对危险度(ORMH)为1.480(95%CI1.237～1.770),吸烟等级与患PAD危险存在剂量反应关系。结论吸烟是患PAD的重要危险因素,随吸烟量的增加,患PAD的危险也增加。     

踝臂指数评价冠心病患者下肢外周动脉病临床研究

目的通过测量踝臂指数(ankle-brachial index, ABI)评价我国住院冠心病(coronary arterial disease, CAD)患者下肢外周动脉病(Peripheral arterial disease, PAD)的发病情况.方法对入院的163例CAD患者进行踝臂指数测定,并进行资料收集和统计学处理.结果 163例CAD患者中发现70例合并外周动脉病(平均ABI 0.63).与非PAD组相比,PAD组患者与年龄 (P=0.000),糖尿病史(P=0.000) 有统计学意义,而与吸烟史(P=0.731), 高血压病史(P=0.187)和血脂异常(P=0.614)无统计学意义.结论通过测量ABI确诊PAD简便易行;CAD患者易合并PAD,冠状动脉旁路移植术(Coronary artery bypass grafting, CABG)患者合并PAD尤为常见;CAD合并PAD多见于高龄和糖尿病.     

踝臂指数评价缺血性卒中患者下肢外周动脉病多中心临床研究

目的:通过测量踝臂指数(ankle-brachialindex,ABI)评价我国缺血性卒中(ischaemic stroke,IS)患者下肢外周动脉病(Peripheral arterial disease,PAD)的患病情况.方法:对入院的423例IS患者进行踝臂指数测定,并进行资料收集和统计学处理.结果:423例缺血性卒中患者中150例合并下肢外周动脉病(平均ABI 0.64),其中只有11例(7.3%)患者得到了明确的诊断.PAD组与非PAD组患者相比,年龄(P=0.000)和糖尿病史(P=0.001)有统计学意义,而吸烟史(P=0.154),高血压病史(P=0.179)和血脂异常(P=0.383)无统计学意义.结论:通过测量ABI确诊下肢PAD简便易行;缺血性卒中患者易合并下肢PAD;缺血性卒中合并下肢PAD多见于高龄和糖尿病患者.     

PREVALENCE AND RISK FACTORS OF PERIPHERAL ARTERIAL DISEASE IN DIABETIC PATIENTS OVER 50 YEARS OLD IN CHINA

Objective To investigate the prevalence of peripheral arterial disease (PAD) in China type 2 diabetic patients and to demonstrate the relationships between putative risk factors and PAD. Methods In total 1 397 type 2 diabetic patients aged 50 years and older were enrolled and determined ankle-brachial index (ABI) and brachial-ankle pulse wave velocity (baPWV) in 15 Class III Grade A hospitals in 7 major cities of China. Results Mean patient age was 63.7±8.2 years and mean duration of diabetes mellitus was 9.39±7.4 years. Two hundreds and seventy-two (19.47%) patients were diagnosed as PAD by ABI <0.9, 122 (18.37%) in male and 150 (20.46%) in female. PAD patients had a significantly longer duration of diabetes mellitus, higher hemoglobin Alc, and a significantly lower mean body mass index than non-PAD ones. Aging, smoking, and systolic blood pressure were found to be positively related with the prevalence of PAD. In terms of lipid profiles, no variable was found to relate with PAD. Notably, baPWV showed as the same significant guiding index for PAD, almost matched with ABI. Conclusions PAD is a common complication in China type 2 diabetic patients. Therefore, PAD screening and treatment should be emphasized for diabetic patients with high risk factors.     

自体外周血干细胞移植联合介入治疗下肢动脉缺血性疾病的效果评价

目的:探讨运用自体外周血干细胞移植与介入联合治疗下肢动脉缺血性疾病,并对其疗效进行临床观察.方法:本研究共入组38例下肢动脉缺血性疾病患者,依自愿原则分组,仅采用介入治疗的19例患者为单独介入组,采用自体外周血进行干细胞移植与介入联合治疗的19例患者为联合治疗组.常规治疗方案两组相同,对两组患者的疼痛感、冷感、间歇跛行、踝肱指数(ankle brachial index,ABI)、侧支血管生成数量等方面的指标进行比较,从而判断两组患者的疗效差异.结果: 在疼痛感、冷感、间歇跛行3方面两组患者均明显降低,差异具有统计学意义(P＜0. 05),ABI评分与侧支血管生成数评分方面,两组均升高,差异具有统计学意义(P＜0. 05).与单独介入组比较,联合治疗组在疼痛感、冷感、间歇跛行方面、ABI评分与侧支血管生成数评分改善更为明显(P＜0. 05).联合治疗组的有效率是89. 5% ,单独介入组的有效率是78. 9% ,联合治疗组效果显著优于单独介入组(P＜0. 05).结论: 自体外周血干细胞移植与介入结合是治疗下肢动脉缺血性疾病安全而有效的方法.     

低踝臂指数与动脉硬化高危男性病死率关系的队列研究

目的研究具有多重动脉硬化危险的男性的踝臂指数（ABI）与全因和心血管疾病（CVD）病死率的关系。方法多中心连续人选内科住院病人中具有多个动脉硬化危险因素的男性病人1941例,年龄36～96岁,进行基线特征调查并平均随访13个月,观察其终点事件的发生率。结果外周动脉疾病（PAD）组的全因病死率（15．4％vs 7．7％）和CVD病死率（5．1％vs 1．8％）均高于正常组,且差异有统计学意义。在重度PAD组、轻度至中度PAD组、临界组和正常对照组中的全因病死率（分别为17．6％,15．2％,10．1％和7．3％）和CVD病死率（分别为14．7％,4．4％,2．9％和1．6％）差异有显著统计学意义（P〈0．001）。经Cox回归分析后,轻至中度PAD组（0．4〈ABI≤0．9）全因死亡的RR为1．585（95％CI：1．126～2．230）。重度PAD组（ABI≤0．4）CVD死亡的RR为4．443（95％CI：1．811～10．902）,轻至中度PAD组CVD死亡的RR为1．859（95％CI：1．091～3．166）。PAD组的全因死亡和CVD死亡生存明显低于正常组。结论ABI是全因死亡和CVD死亡的独立危险因素,ABI越低CVD病死率可能越高。     

中西医结合治疗糖尿病周围血管病变临床疗效观察

[目的]观察中西医结合治疗糖尿病周围血管病变的临床疗效。[方法]将入选的糖尿病周围血管病变患者60例,随机分为治疗组30例和对照组30例,两组均常规治疗。治疗组给予复荣通脉胶囊口服及黄芪注射液静脉点滴联合西洛他唑口服,对照组单用西洛他唑片口服,观察两组临床症状、足背温度、踝肱动脉指数(ABI)的变化。[结果]治疗组在改善临床症状、足背温度、ABI等方面明显优于对照组(P0.05,P0.01),且未见明显不良反应。[结论]中西医结合治疗糖尿病周围血管病变,疗效优于单用西洛他唑组。     

糖尿病膝下动脉病变经皮腔内血管成形术的短期疗效

目的 评价糖尿病膝下动脉病变经皮腔内血管成形术(PTA)的临床短期疗效.方法 本组35例糖尿病合并缺血性下肢动脉病变患者,男20例,女15例,年龄50～81岁,中位年龄为69岁.Rutherford-Becker分级Ⅰ级6例,临床表现为中度以上间歇性跛行;Ⅱ级10例,临床表现为缺血性静息痛;Ⅲ级19例,为不同程度的溃疡和坏疽.所有患者术前均行患肢CT三维重建(CTA)及数字减影血管造影(DSA)检查,术后定期门诊随访,观察记录临床症状和体征变化,并测定1、3、6和12个月患肢踝肱指数(ABI).结果 35例患者53侧肢体共60支膝下动脉存在狭窄或闭塞,其中51支动脉通过球囊扩张得以开通,PTA成功率为85.0%.所有患者的疼痛症状均明显缓解,32例患者单位时间步行距离和固定距离步行时间均恢复正常.术后12个月ABI为0.65,与术前(0.49)的差异无统计学意义(P0.05).结论 PTA是治疗糖尿病膝下动脉病变安全有效的方法.     

西洛他唑联合复方芎蝎胶囊治疗糖尿病下肢血管病变

目的：观察西洛他唑联合复方芎蝎胶囊治疗糖尿病下肢血管病变的疗效。方法采用随机抽样法将171例糖尿病下肢血管病变患者分为3组,实验组,对照1组和对照2组,各57例,3组均接受常规基础治疗,实验组加用西洛他唑联合复方芎蝎胶囊,对照1组加用西洛他唑,对照2组不加用其他药物。1个疗程周期为60 d,1个疗程后检测各组下肢血管彩超以及踝肱指数（ ABI）,并统计疗效。结果实验组总有效率87.7%,对照1组为70.2%,对照2组为59.6%,实验组优于对照1组和对照2组（P ＜0.05,P ＜0.01）;3组胫前动脉血液流速和踝肱指数均有所改善,但实验组优于对照1组和对照2组（P ＜0.05,P ＜0.01）。结论西洛他唑联合复方芎蝎胶囊治疗糖尿病下肢血管病变,能改善胫前动脉血液流速和踝肱指数,改善临床症状。